Chronic Kidney Disease
Tight control of inflammation in RA may provide additional benefits for preventing the development of CKD.
Study confirms the noninferiority of semaglutide.
PPI use was associated with 10% increased odds of CKD and 76% increased odds of death.
Review links atrial fibrillation to increased risk for cardiovascular events, kidney disease, not just stroke.
Higher albuminuria emerges as a significant predictor of hospitalization for GI bleeding.
Enalapril plus folic acid treatment was associated with a 56% reduction in the odds of CKD progression compared with enalapril alone.
In a study, CKD was 16% less likely to develop in low adherers to a DASH dietary pattern.
Significantly higher nighttime systolic blood pressure, especially in patients with diabetes and low eGFR.
A hemoglobin level of 10.5 g/dL offers the optimal balance of cost and quality adjusted life years, researchers conclude.
The odds of developing anemia were 2-fold greater among patients with than without diabetes mellitus.
Study demonstrates a novel effect of patiromer treatment in hyperkalemic CKD patients
Anemia was associated with impaired activity levels at CKD stages 3, 4, and dialysis.
Patients who took CVD medications less than 60% of the time before starting dialysis had a 21% increased risk of early death after dialysis initiation.
Doubling of serum creatinine occured in 1,262 patients studied.
Researchers found a U-shaped relationship between HDL cholesterol and premature death across all levels of kidney function.
Black CKD patients with strict blood pressure control had a 19% lower risk of premature death.
The availability of direct-acting antiviral drugs may enable eradication of hepatitis C virus and improve outcomes.
Since early 2000s, little increase in prevalence of stage 3 and 4 chronic kidney disease.
Patients who made more frequent predialysis visits to a nephrologist had a lower risk of severe anemia at dialysis initiation.
A post-hoc analysis was conducted on the effect of saxagliptin 2.5 mg and 5 mg vs. placebo on glycemic measures.
Over 33 months, the 25-hydroxyvitamin D level of ergocalciferol recipients increased significantly from 15.14 to 37.32 ng/mL.
Notably, gliclazide did not appear superior to other sulfonylureas.
Study implicates higher consumption of advanced glycation end products through dietary fat.
Nearly 28% of study participants demonstrated difficulty with 1 or more activities of daily living, a history of falls, and cognitive impairment.
Patients with depression were younger, had higher eGFR, and more comorbidities.
Highest vs lowest quartile of intake is associated with a 40% increased risk.
Patients with non-dialysis chronic kidney disease (CKD) may be at elevated risk for hip fracture, according the Journal of Bone and Mineral Research.
Odds of cardiovascular mortality 14.8% higher in black Americans with both conditions.
High potassium levels associated with the use of renin-angiotensin-aldosterone system inhibitors limit their use in CKD patients.
Incident or worsening nephropathy was observed in 12.7% of patients receiving empagliflozin compared with 18.8% of those receiving placebo.
Renal and Urology News Articles
- Hypogonadism in Male HD Patients Linked to Poor ESA Response
- Risk Factors for Post-TPTx Severe Hypocalcemia Identified
- Elevated CRP Linked With CKD Risk in Rheumatoid Arthritis
- Losartan Reduces Aldosterone in Hypertension Without Sleep Apnea
- 10-Year Mortality for Localized PCa Does Not Differ by Treatment Choice
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)